Bronchodilator responsiveness: interpret with caution

James Fingleton,1 Mark Weatherall,2 Richard Beasley1

Bronchodilator responsiveness (BDR) is widely considered to be a key diagnostic criterion for asthma, and is used to differentiate asthma from chronic obstructive pulmonary disease (COPD). Currently, the threshold of a 12% increase in FEV1 from baseline following inhaled salbutamol, with at least 200 ml increase in absolute terms, is recommended as a response indicative of asthma,1 although recent British guidelines recognise the poor discriminatory function of this criterion.2 Thus, despite this criterion being commonly used in clinical practice, there is uncertainty regarding its clinical utility, in particular its ability to differentiate asthma from COPD, or indeed, normal subjects.

One approach to enable a better understanding of the clinical utility of BDR is to determine the worldwide distribution of BDR in health and disease, which has been undertaken by Tan and colleagues, and reported in Thorax.3 The authors report BDR in terms of change in FEV1 and FVC following 200 μg of salbutamol delivered by metered dose inhaler via a spacer, in around 10 000 adults aged 40 years and older from 14 countries in North America, Europe, Asia and Africa who participated in the Burden of Obstructive Lung Disease study. The Burden of Obstructive Lung Disease methodology is robust and has many strengths, not the least of which is its multi-national nature and the central review of all spirometry, which increases confidence in the reliability of the lung function values obtained. The results of this study are, therefore, likely to be unbiased, and precise estimates of the populations described. The authors report that the most reliable metric of BDR was the change in FEV1 relative to predicted FEV1 (ΔFEV1p). In healthy non-smokers, the threshold or upper limit of normality for ΔFEV1p was 10% without heterogeneity across populations. The authors also report the more commonly used measure of change in FEV1 from baseline, and give a threshold of 12%.

The values reported are consistent with the current ATS/ERS Task Force cut-offs for defining a clinically significant bronchodilator response.4 The authors propose that this strengthens the applicability of this measure for global interpretation of bronchodilator testing on the basis that values above this cut-off are beyond 95% of the distribution of healthy individuals and, as such, can be considered ‘abnormal,’ thus reflecting the presence of disease.

Although it is also proposed that such a cut-off discriminates healthy subjects from obstructed individuals, this unfortunately is not the case. Further analysis of their data indicates that BDR discriminates poorly between healthy subjects and individuals with airflow obstruction regardless of comorbid asthma (FEV1/FVC <0.7, FEV1 % predicted <80%). The authors found that BDR was consistent with a Gaussian (normal) distribution. The mean (SD) values for BDR expressed as ΔFEV1p in healthy individuals was 2.6% (4.8) and 4.2% (5.7) in obstructed individuals. The Gaussian distribution gives the proportion of those above the cut-off of 10% as 6.1% (healthy), and 15.4% (obstructed). For healthy versus obstructed, the sensitivity was 15.4%, specificity 93.9%, likelihood ratio test positive 2.5, and test negative 0.9. These values, particularly for likelihood ratio negative, are not consistent with a good discriminatory test. Values for likelihood ratio positive and negative that are considered to represent clinically relevant changes in post-test probabilities of disease are 5 and 0.2, respectively.

1Medical Research Institute of New Zealand, Wellington, New Zealand; 2University of Otago Wellington, Wellington, New Zealand
Correspondence to Professor Richard Beasley, Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington 6242, New Zealand; richard.beasley@mriw.ac.nz
BDR has also been widely used to assess potential treatment response. However, the lack of an acute BDR does not preclude subsequent benefit from maintenance inhaled long-acting bronchodilator therapy. 10

These findings have implications not only for diagnosis but also in the generalisability of randomised controlled trials (RCTs) on which both guidelines and clinical practice are based. The understandable desire to have objective criteria governing the selection of trial participants leads to the unintended consequence that the results of such trials have limited generalisability to the majority of patients with airways disease. Most asthma RCTs require subjects to have BDR of at least 15% increase in FEV1 from baseline, and COPD RCTs require subjects to have <10% increase in FEV1. In a random population, these criteria alone result in around 76% of adults with asthma and 29% of adults with COPD being ineligible for the majority of RCTs on which their management has been based. 11 12

In conclusion, there is considerable overlap in BDR in health and disease, and between asthma and COPD. It has recently been argued that spirometry is an essential tool in patient evaluation, but dangerous for disease diagnosis, and the term, COPD, should only be used in the appropriate clinical (diagnostic) context. 13 Similarly, we would propose that BDR testing is interpreted with caution, and that it is considered in its clinical context because a large proportion of patients with asthma and COPD will have values within the healthy range.

Contributors All authors contributed to the drafting of this editorial. MW undertook the statistical analyses.

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

REFERENCES